| dapagliflozin / Generic mfg. |
2017-004889-10: Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory study Dapagliflozin effect on generation of red blood cells and physical fitness in patients with type 2 diabetes - a randomized, double-blind, controlled, parallel group, exploratory stud |
|
|
| Not yet recruiting | 4 | 75 | Europe | Forxiga, Film-coated tablet, Tablet, Forxiga, HCT Hexal | University Hospital Tuebingen, AstrZeneca GmbH | Patients with T2DM and hypertension aged 40 to 70 years (including) Patienten mit Diabetes mellitus Typ 2 im Alter von 40 bis 70 Jahren (einschließlich), Patients with T2DM and hypertension aged 40 to 70 years (including) Patienten mit Diabetes mellitus Typ 2 und Bluthochdruck im Alter von 40 bis 70 Jahren (einschließlich), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT06785116: A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP) |
|
|
| Recruiting | 4 | 200 | US | Placebo, Dapagliflozin 10mg Tab, Farxiga | University of Michigan, Society for Maternal-Fetal Medicine Foundation, American Association of Obstetricians and Gynecologists Foundation | Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication | 08/28 | 08/28 | | |
NCT07147114: Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) |
|
|
| Recruiting | 4 | 64 | RoW | Combination therapy, Maciten Tab. 10mg, Monotherapy, Dapozin Tab. 10mg or 5mg | Gachon University Gil Medical Center | Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF, Group 2 Pulmonary Hypertension | 09/27 | 09/27 | | |
ChiCTR2500106491: An interventional study on the impact of nocturnal hypertention on the prognosis of heart failure with preserved ejection fraction-a prospective, randomized, praralle controlled study |
|
|
| Recruiting | 4 | 254 | | Sacubitril/valsartan 100-400mg qn ; Sacubitril/valsartan 100-400mg qn and Dapagliflozin 5-10mg qn | The Third People's Hospital of Chengdu; The Third People's Hospital of Chengdu, Sichuan Provincial Health Commission, Chengdu Third People's Hospital | Hypertension, Heart failure | | | | |
2015-004164-11: Effect of the glucose-lowering drug dapagliflozin on vascular function and blood pressure Effetto dell’antidiabetico orale dapagliflozin sulla funzione vascolare e sulla pressione arteriosa |
|
|
| Completed | 3 | 55 | Europe | FORXIGA, ESIDREX, NON DISPONIBILE, Film-coated tablet, Tablet, FORXIGA - 10 MG - COMPRESSE RIVESTITE CON FILM- USO ORALE - BLISTER CALENDARIZZATO (ALU/ALU) - 28 COMPRESSE, ESIDREX - 25 MG COMPRESSE 20 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA, AstraZeneca S.p.A | Arterial hypertension Ipertensione arteriosa, Arterial hypertension Ipertensione arteriosa, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
BaxDuo-Pacific, NCT06742723 / 2023-506460-14-00: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure |
|
|
| Recruiting | 3 | 5000 | Europe, Canada, Japan, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat CIN-107, Placebo/dapagliflozin | AstraZeneca, AstraZeneca AB | Chronic Kidney Disease and Hypertension | 12/29 | 12/29 | | |
THP-001-031, NCT06647745: A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension |
|
|
| Recruiting | 3 | 221 | RoW | THP-00101, Forxiga Tab. 10mg, THP-00102, Micardis Tab. 80mg, THP-00103, Micardis Tab. 40mg, THP-00104, Placebo of Fociga Tab. 10mg, THP-00105, Placebo of Micardis Tab. 80mg, THP-00106, Placebo of Micardis Tab. 40mg | THPharm Corp. | Type 2 Diabetes, Hypertension | 06/26 | 12/26 | | |
NCT06268873 / 2023-506457-38-00: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. |
|
|
| Active, not recruiting | 3 | 2554 | Europe, Canada, Japan, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat CIN-107, Dapagliflozin in combination with placebo | AstraZeneca, AstraZeneca AB | Chronic Kidney Disease and Hypertension | 02/28 | 02/28 | | |
| Completed | 2/3 | 34 | Europe | Dapagliflozin 10mg Tab, Placebo | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, AstraZeneca | Chronic Kidney Disease, Diabetes Mellitus, Type 2, Hypertension | 09/24 | 09/24 | | |
D6972C00003, 2023-506457-38-00: A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressure |
|
|
| Active, not recruiting | 2/3 | 675 | Europe | Forxiga 10 mg film-coated tablets, Baxdrostat, Baxdrostat placebo | Astrazeneca AB, AstraZeneca AB | Chronic kidney disease (CKD) and hypertension. | | | | |
D6972C00002, 2023-506460-14-00: A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressure |
|
|
| Recruiting | 2/3 | 1134 | Europe | Forxiga 10 mg film-coated tablets, Baxdrostat placebo, Baxdrostat | Astrazeneca AB, AstraZeneca AB | Chronic kidney disease (CKD) and hypertension. | | | | |
| Not yet recruiting | 2/3 | 3112 | Europe | Dapagliflozin Ascend 10 mg Filmtabletten, Placebo for Dapagliflozin | Universitaetsklinikum Schleswig-Holstein A, EUROPEAN HEALTH AND DIGITAL EXECUTIVE AGENCY (HADEA) | Arterial Hypertension | | | | |
2021-006787-25: The effects of dapagliflozin in patients with elevated blood pressure in the lungs |
|
|
| Not yet recruiting | 2 | 52 | Europe | Forxiga, Tablet, Forxiga (dapagliflozin) | Rigshospitalet The Heart Center, Rigshospitalet The Heart Center | Pulmonary arterial hypertensionChronic thromboembolic pulmonary hypertension, Elevated blood pressure in the lungs of unknown originChronic thrombi in the lungs with elevated blood pressure., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-004073-31: Treating mild kidney failure over 24 weeks in people with or without type 2 diabetes or high blood pressure |
|
|
| Not yet recruiting | 2 | 340 | Europe | dapagliflozin, Tablet, Forxiga | University Medical Center Groningen, AstraZeneca | Microalbuminuria, Mild kidney failure, Diseases [C] - Hormonal diseases [C19] | | | | |
| Terminated | 2 | 9 | Europe | Dapagliflozin 10Mg Tab, Placebo | University Medical Center Groningen, AstraZeneca | Albuminuria | 02/23 | 02/23 | | |
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria |
|
|
| Completed | 2 | 60 | US | Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD | Mineralys Therapeutics Inc. | Chronic Kidney Disease | 02/25 | 04/25 | | |
| Completed | 2 | 52 | Europe | Dapagliflozin 10 MG [Farxiga], Placebo | Mads Ersbøll, Rigshospitalet The Heart Center | Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 01/26 | 01/26 | | |
| Terminated | 2 | 205 | Europe, US, RoW | Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin | AstraZeneca, AstraZeneca AB | Liver Cirrhosis | 05/25 | 07/25 | | |
BaxDuo-Baltic, NCT07222917: A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. |
|
|
| Recruiting | 2 | 218 | Europe, Canada, US, RoW | Baxdrostat/dapagliflozin, Baxdrostat/Placebo | AstraZeneca | Chronic Kidney Disease and Hypertension | 05/27 | 05/27 | | |
| Completed | 1/2 | 52 | Europe | PLACEBO, Forxiga 10 mg film-coated tablets | Rigshospitalet, Rigshospitalet The Heart Center | Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension | | | | |
D6972C00006, 2025-522407-23-00: A Phase IIb study to evaluate the effect of combination of dapagliflozin and baxdrostat compared with baxdrostat alone in participants with chronic kidney disease and high blood pressure |
|
|
| Not yet recruiting | 1/2 | 28 | Europe | Baxdrostat, Dapagliflozin Placebo, Forxiga 10 mg film-coated tablets | AstraZeneca AB, AstraZeneca AB | Chronic kidney disease (CKD) and hypertension. | | | | |
NCT06063109: A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin. |
|
|
| Completed | 1 | 51 | RoW | THP-00101 (Dapagliflozin) 10mg, Forxiga Tab. 10mg, THP-00102 (Telmisartan) 80mg, Micardis Tab. 80mg | THPharm Corp. | Hypertension, Diabetes Mellitus, Type 2 | 11/23 | 11/23 | | |
NCT06612086: Dapagliflozin in Mangement of Pulmonary Hypertension Patients |
|
|
| Not yet recruiting | 1 | 70 | RoW | Dapagliflozin (Forxiga) | Assiut University | Pulmonary Hypertension | 09/25 | 10/26 | | |
| Recruiting | N/A | 30 | Europe | SGLT2 inhibitor, Dapagliflozin, Empagliflozin, Canagliflozin | University of Turin, Italy | Diabetes Mellitus, Type 2, Arterial Hypertension, Body Weight Changes | 07/20 | 10/20 | | |
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) |
|
|
| Recruiting | N/A | 5000 | Canada, US | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab, Albuterol, Beclomethasone, Bivalirudin, Bumetanide, Cephalexin, Chlorothiazide, Clonidine, Dapagliflozin, Diazoxide, Drug-Drug Interaction Combinations, Fluticasone, Ganciclovir, Hydralazine, Hydrochlorothiazide, Valganciclovir | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome | 03/27 | 07/27 | | |
NCT05970237: A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension |
|
|
| Recruiting | N/A | 9000 | RoW | | Boryung Pharmaceutical Co., Ltd | Diabetes Mellitus, Hypertension | 10/25 | 10/25 | | |
ICDDTKZ26, NCT07303556: Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs |
|
|
| Active, not recruiting | N/A | 120 | RoW | Tirzepatide (Mounjaro), Dual GIP/GLP-1 receptor agonist, dapagliflozin, empagliflozin, metformin, Forxiga, Jardiance, Siofor | Nazarbayev University | Heart Failure, Diabete Type 2, Arterial Hypertension | 07/25 | 11/26 | | |
NCT06778330: The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension |
|
|
| Completed | N/A | 100 | RoW | Dapagliflozin (DAPA), Sildenafil | Fayoum University | Heart Failure NYHA Class II | 08/25 | 08/25 | | |
PROBE-RCT, ChiCTR2600116590: The effect of SGLT2 inhibitors on left atrial Function in patients with Hypertension: A prospective, Randomized, open-access, blinded endpoint assessment study |
|
|
| Not yet recruiting | N/A | 148 | | In addition to standard antihypertensive therapy (SoC), one tablet of SGLT2 inhibitor (dapagliflozin 10 mg or empagliflozin 10 mg) was administered daily. Other antihypertensive medications were to be kept as stable as possible; any adjustments according to guidelines required detailed documentation.; Continue current standard antihypertensive therapy (SoC) without the use of SGLT2 inhibitors. | The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, Self-funded | Hypertension | | | | |
